Idorsia Pharmaceuticals Ltd

Actelion Pharmaceuticals Ltd

John Gatfield

Martin Bolli

Corinna Grisostomi

Lubos Remen

Cornelia Zumbrunn

Bibia Heidmann

Christoph Sager

Christoph Boss

Thierry Sifferlen

Markus Gude

Christine Brotschi

Jodi T Williams

Romain Siegrist

Simon Stamm

Olivier Bezencon

Daniel Bur

The present invention relates to compounds of Formula (I) wherein Ar, R, R, R, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

(2-acetamidyl)thio-beta-D-galactopyranoside derivatives

The present invention relates to compounds of Formula (I) wherein Ar, Ar, R, R, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

(Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives

The present invention relates to compounds of Formula (I) wherein Ar, Rand Rare as described in the description, and A is 4,5-dihydroisoxazole-3,5-diyl, imidazolidin-4-one-1,3-diyl, oxazol-2-one-3,5-diyl and oxazolidine-2-one-3,5-diyl, 1,2,3-triazole-1,4-diyl, isoxazole-3,5-diyl, imidazole-1, 4-diyl, and isothiazole-3,5-diyl; and their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Alpha-D-galactopyranoside derivatives

The present invention relates to compounds of Formula (I) wherein Ar, A, B, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Spiro derivatives of Alpha-D-galactopyranosides

The present invention relates to compounds of Formula (I) wherein X, Ar, Ar, L, n, m, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Hydroxyheterocycloalkane-carbamoyl derivatives

The present invention relates to compounds of Formula (I)

2-hydroxycycloalkane-1-carbamoyl

The present invention relates to compounds of Formula (I) wherein Ar, Ar, L, n, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives

The invention relates to compounds of formula (I) 

Triazole compounds as T-type calcium channel blockers

The invention relates to compounds of formula (I) wherein X, Y, R, R, (R), and (R)are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.

Pyrazole compounds and their use as T-type calcium channel blockers

The present invention relates to (S)-proline sulfonamide compounds of formula (I) wherein Rand Rare as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.

Growing community of inventors

Allschwil, Switzerland

John Gatfield